Back

Reverse cardiac remodeling following with sacubitril/valsartan in heart failure: comparison between ischemic and non-ischemic etiology

29 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Drugs, devices, and diagnostics in heart failure Ventricular Remodelling ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speakers

Photo
Professor Erberto Carluccio

Hospital Santa Maria Della Misericordia, Perugia (Italy)

Photo
Professor Giuseppe Ambrosio

University of Perugia, Perugia (Italy)

7 More presentations in this session

Presentation thumbnail
Effects of beta-blockers on exercise capacity and hemodynamic response during CPET with echocardiography in heart failure with preserved ejection fraction
Doctor S. Dhont (Genk, BE) Doctor P. Bertrand (Genk, BE)
Abstract Slides Video
Presentation thumbnail
Effects of sodium-glucose cotransporter-2 inhibitors on left ventricular-arterial coupling and myocardial extracellular volume in patients with type 2 diabetes mellitus and HFpEF
Doctor A. Marathonitis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Finerenone-related risk of hypotension in patients with heart failure with mildly reduced or preserved ejection fraction
Doctor A. Foa' (Bologna, IT)
Abstract Slides Video
Presentation thumbnail
Hemodynamic effects of lactate infusion in chronic heart failure patients
Doctor N. Abild Jespersen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Resynchronization reduces arginase activity in red blood cells of heart failure patients with dyssynchrony
Doctor K. Ljung (Stockholm, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Drugs, devices, and diagnostics in heart failure

The Event

Event poster

ESC Congress 2025

29 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Session
Smaller trials: cardiac function and remodelling
thumbnail
Congress Presentation
Comparison of clinical characteristics and survival between ischemic and non-ischemic patients heart failure patients with reduced ejection fraction: an observational study
thumbnail
Congress Presentation
The anti-remodeling effect of sacubitril/valsartan in myocardial samples of end-stage heart failure patients

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources